Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature

Stefanie Slot*, Reinier A. P. Raymakers, Nicolaas Schaap, Lambert F. R. Span, Harry R. Koene, Sabina Kersting, Peter A. W. te Boekhorst, Matthijs Westerman, Harry C. Schouten, Sonja Zweegman

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)624-634
Number of pages11
JournalClinical Lymphoma Myeloma & Leukemia
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • Dosing
  • JAK2 inhibitor
  • Platelet count
  • Safety
  • Treatment
  • POLYCYTHEMIA-VERA
  • OPEN-LABEL
  • EFFICACY
  • MULTICENTER
  • SAFETY
  • CRITERIA
  • THERAPY

Cite this

Slot, S., Raymakers, R. A. P., Schaap, N., Span, L. F. R., Koene, H. R., Kersting, S., Boekhorst, P. A. W. T., Westerman, M., Schouten, H. C., & Zweegman, S. (2019). Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature. Clinical Lymphoma Myeloma & Leukemia, 19(10), 624-634. https://doi.org/10.1016/j.clml.2019.07.005